Structure Therapeutics (GPCR) Common Equity (2022 - 2026)

Structure Therapeutics' Common Equity history runs 5 years deep, the most recent figure standing at $1.4 billion for Q1 2026.

• In Q1 2026, Common Equity rose 75.48% year-over-year to $1.4 billion; the TTM figure through Mar 2026 stood at $1.4 billion (up 75.48% YoY), while the FY2025 annual figure was $1.5 billion, up 75.34% from the prior year.
• Common Equity for Q1 2026 stood at $1.4 billion, down from $1.5 billion in the prior quarter.
• The five-year high for Common Equity was $1.5 billion in Q4 2025, with the low at -$115.1 million in Q4 2022.
• The 5-year median for Common Equity is $453.0 million (2023), against an average of $538.3 million.
• The sharpest annual moves came in 2023 and 2025: Common Equity jumped 493.4% in 2023, then fell 16.17% in 2025.
• Structure Therapeutics' Common Equity stood at -$115.1 million in 2022, then surged by 493.4% to $453.0 million in 2023, then surged by 90.93% to $864.8 million in 2024, then surged by 75.34% to $1.5 billion in 2025, then fell by 4.57% to $1.4 billion in 2026.
• Business Quant data shows GPCR's Common Equity at $1.4 billion in Q1 2026, $1.5 billion in Q4 2025, and $770.0 million in Q3 2025.